Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).

Trial Profile

A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms HERBIS-3

Most Recent Events

  • 20 Feb 2019 Status changed from active, no longer recruiting to completed.
  • 18 Aug 2012 Actual initiation date changed from 1 Aug 2011 to 22 Aug 2011 added as reported by University Hospital Medical Information Network - Japan
  • 22 Nov 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top